Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefoperazone + metronidazole is a combination of two antibiotics used primarily for the prevention and treatment of infections, especially those involving mixed aerobic and anaerobic bacteria. Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, providing broad-spectrum activity against many Gram-negative and some Gram-positive organisms. Metronidazole is a nitroimidazole antibiotic effective against most anaerobic bacteria and certain protozoa; it works by disrupting DNA synthesis in susceptible organisms. This combination is commonly used as surgical prophylaxis in procedures with high risk of anaerobic infection (such as hepatobiliary, colorectal, or upper gastrointestinal surgeries) and for treating intra-abdominal infections[1][5]. The combined use targets both aerobic pathogens (cefoperazone) and anaerobes (metronidazole), reducing postoperative infectious complications more effectively than monotherapy[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefoperazone + metronidazole.